Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Astrocytoma

Astrocytoma

Astrocytomas are a type of glial tumor that arise from astrocytes, the star-shaped glial cells found in the brain and spinal cord.
These tumors can occur in both children and adults, with varying degrees of aggressiveness.
Astrocytomas range from low-grade, slow-growing tumors to high-grade, rapidly proliferating glioblastomas.
Symptoms may include headaches, seizures, vision problems, and neurological deficits, depending on the tumor's location and infiltration.
Accurate diagnosis and optimal treatment planning are crucial for managing astrocytomas and improving patient outcomes.
PubCompare.ai leverages AI-driven comparisons to help researchers streamline their work and uncover insights more efficiently when studying these complex brain tumors.

Most cited protocols related to «Astrocytoma»

1
Comparing Methylation-Based CNS Tumor Classification
To compare our methylation-based classification of CNS tumours with described methylation classes of brain tumours by the Cancer Genome Atlas (TCGA) project, we downloaded the pre-processed methylation dataset described in Ceccarelli et al. 201618 including methylation data of 418 low grade glioma and 377 glioblastoma samples analysed by using the Illumina 450k array or 27k array platforms. To classify our samples according to the TCGA pan-glioma DNA methylation classification, we trained a Random Forest classifier on this dataset using the 1,300 CpG probe signature provided by the authors and using the default settings of the Random Forest algorithms implemented in the R package randomForest. The results of this classification for astrocytomas, oligodendrogliomas and glioblastomas are shown in Extended Data Figure 3d and are given on a case-by-case basis in Supplementary Table 2 and 4.
Capper D., Jones D.T., Sill M., Hovestadt V., Schrimpf D., Sturm D., Koelsche C., Sahm F., Chavez L., Reuss D.E., Kratz A., Wefers A.K., Huang K., Pajtler K.W., Schweizer L., Stichel D., Olar A., Engel N.W., Lindenberg K., Harter P.N., Braczynski A., Plate K.H., Dohmen H., Garvalov B.K., Coras R., Hölsken A., Hewer E., Bewerunge-Hudler M., Schick M., Fischer R., Beschorner R., Schittenhelm J., Staszewski O., Wani K., Varlet P., Pages M., Temming P., Lohmann D., Selt F., Witt H., Milde T., Witt O., Aronica E., Giangaspero F., Rushing E., Scheurlen W., Geisenberger C., Rodriguez F.J., Becker A., Preusser M., Haberler C., Bjerkvig R., Cryan J., Farrell M., Deckert M., Hench J., Frank S., Serrano J., Kannan K., Tsirigos A., Brück W., Hofer S., Brehmer S., Seiz-Rosenhagen M., Hänggi D., Hans V., Rozsnoki S., Hansford J.R., Kohlhof P., Kristensen B.W., Lechner M., Lopes B., Mawrin C., Ketter R., Kulozik A., Khatib Z., Heppner F., Koch A., Jouvet A., Keohane C., Mühleisen H., Mueller W., Pohl U., Prinz M., Benner A., Zapatka M., Gottardo N.G., Driever P.H., Kramm C.M., Müller H.L., Rutkowski S., von Hoff K., Frühwald M.C., Gnekow A., Fleischhack G., Tippelt S., Calaminus G., Monoranu C.M., Perry A., Jones C., Jacques T.S., Radlwimmer B., Gessi M., Pietsch T., Schramm J., Schackert G., Westphal M., Reifenberger G., Wesseling P., Weller M., Collins V.P., Blümcke I., Bendszus M., Debus J., Huang A., Jabado N., Northcott P.A., Paulus W., Gajjar A., Robinson G., Taylor M.D., Jaunmuktane Z., Ryzhova M., Platten M., Unterberg A., Wick W., Karajannis M.A., Mittelbronn M., Acker T., Hartmann C., Aldape K., Schüller U., Buslei R., Lichter P., Kool M., Herold-Mende C., Ellison D.W., Hasselblatt M., Snuderl M., Brandner S., Korshunov A., von Deimling A, & Pfister S.M. (2018). DNA methylation-based classification of central nervous system tumours. Nature, 555(7697), 469-474.
Publication 2018
Astrocytoma Brain Neoplasm, Malignant Central Nervous System Neoplasms DNA Methylation Genome Glioblastoma Glioblastoma Multiforme Glioma Malignant Neoplasms Methylation Neoplasms Oligodendroglioma
2
Comparing Methylation-Based CNS Tumor Classification
To compare our methylation-based classification of CNS tumours with described methylation classes of brain tumours by the Cancer Genome Atlas (TCGA) project, we downloaded the pre-processed methylation dataset described in Ceccarelli et al. 201618 including methylation data of 418 low grade glioma and 377 glioblastoma samples analysed by using the Illumina 450k array or 27k array platforms. To classify our samples according to the TCGA pan-glioma DNA methylation classification, we trained a Random Forest classifier on this dataset using the 1,300 CpG probe signature provided by the authors and using the default settings of the Random Forest algorithms implemented in the R package randomForest. The results of this classification for astrocytomas, oligodendrogliomas and glioblastomas are shown in Extended Data Figure 3d and are given on a case-by-case basis in Supplementary Table 2 and 4.
Capper D., Jones D.T., Sill M., Hovestadt V., Schrimpf D., Sturm D., Koelsche C., Sahm F., Chavez L., Reuss D.E., Kratz A., Wefers A.K., Huang K., Pajtler K.W., Schweizer L., Stichel D., Olar A., Engel N.W., Lindenberg K., Harter P.N., Braczynski A., Plate K.H., Dohmen H., Garvalov B.K., Coras R., Hölsken A., Hewer E., Bewerunge-Hudler M., Schick M., Fischer R., Beschorner R., Schittenhelm J., Staszewski O., Wani K., Varlet P., Pages M., Temming P., Lohmann D., Selt F., Witt H., Milde T., Witt O., Aronica E., Giangaspero F., Rushing E., Scheurlen W., Geisenberger C., Rodriguez F.J., Becker A., Preusser M., Haberler C., Bjerkvig R., Cryan J., Farrell M., Deckert M., Hench J., Frank S., Serrano J., Kannan K., Tsirigos A., Brück W., Hofer S., Brehmer S., Seiz-Rosenhagen M., Hänggi D., Hans V., Rozsnoki S., Hansford J.R., Kohlhof P., Kristensen B.W., Lechner M., Lopes B., Mawrin C., Ketter R., Kulozik A., Khatib Z., Heppner F., Koch A., Jouvet A., Keohane C., Mühleisen H., Mueller W., Pohl U., Prinz M., Benner A., Zapatka M., Gottardo N.G., Driever P.H., Kramm C.M., Müller H.L., Rutkowski S., von Hoff K., Frühwald M.C., Gnekow A., Fleischhack G., Tippelt S., Calaminus G., Monoranu C.M., Perry A., Jones C., Jacques T.S., Radlwimmer B., Gessi M., Pietsch T., Schramm J., Schackert G., Westphal M., Reifenberger G., Wesseling P., Weller M., Collins V.P., Blümcke I., Bendszus M., Debus J., Huang A., Jabado N., Northcott P.A., Paulus W., Gajjar A., Robinson G., Taylor M.D., Jaunmuktane Z., Ryzhova M., Platten M., Unterberg A., Wick W., Karajannis M.A., Mittelbronn M., Acker T., Hartmann C., Aldape K., Schüller U., Buslei R., Lichter P., Kool M., Herold-Mende C., Ellison D.W., Hasselblatt M., Snuderl M., Brandner S., Korshunov A., von Deimling A, & Pfister S.M. (2018). DNA methylation-based classification of central nervous system tumours. Nature, 555(7697), 469-474.
Publication 2018
Astrocytoma Brain Neoplasm, Malignant Central Nervous System Neoplasms DNA Methylation Genome Glioblastoma Glioblastoma Multiforme Glioma Malignant Neoplasms Methylation Neoplasms Oligodendroglioma
3
Adult Lower-Grade Glioma Molecular Profiling
The tumor samples we analyzed were from 293 adults with previously untreated lower-grade gliomas (WHO grades II and III), including 100 astrocytomas, 77 oligoastrocytomas, and 116 oligodendrogliomas. Pediatric lower-grade gliomas were excluded; their molecular pathogenesis is distinct from that of lower-grade gliomas in adults.20 (link),21 (link) Diagnoses were established at the contributing institutions; neuropathologists in our consortium reviewed the diagnoses and ensured the quality of the diagnoses and of the tissue for molecular profiling (see Supplementary Appendix 1, available with the full text of this article at NEJM.org, for sample inclusion criteria). Patient characteristics are described in Table 1, and in Table S1 (Supplementary Appendix 2) and Table S2 in Supplementary Appendix 1. We obtained appropriate consent from relevant institutional review boards, which coordinated the consent process at each tissue-source site; written informed consent was obtained from all participants. The patients’ ages, tumor locations, clinical histories and outcomes, tumor histologic classifications, and tumor grades were typical of adults with a diagnosis of diffuse glioma.1 ,2 (link)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015). The New England journal of medicine, 372(26), 2481-2498.
Publication 2015
Adult Astrocytoma Diagnosis Ethics Committees, Research Glioma Mixed Oligodendroglioma-Astrocytoma Neoplasms Neoplasms by Site Neuropathologist Oligodendroglioma pathogenesis Patients Tissues
4
Molecular Characterization of Glioma Tumors
To better understand the genetic pathogenesis of gliomas and begin to identify potential glioma-specific molecular therapeutic targets, consistent molecular characterization of a large number of tumors is required.
This process was undertaken under a national prospective clinical trial that would eventually be IRB-approved both within the NCI intramural program as well as through both CTEP-sponsored adult brain tumor consortia (NABTT and NABTC protocol # 01-07). With the activation of this study, we collected matched tumor, blood and plasma from the 14 contributing institutions (National Institutes of Health, Henry Ford Hospital, Thomas Jefferson University, University of California San Francisco, H. Lee Moffitt Hospital, University of Wisconsin, University of Pittsburgh Medical Center, University of California Los Angeles, M.D. Anderson Cancer Center, Dana Farber Cancer Center, Duke University, Johns Hopkins University, Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center). All tissue collected is sent to the Neuro-Oncology Branch laboratory for processing. The samples were provided as snap frozen sections of areas immediately adjacent to the region used for the histopathological diagnosis. Initial histopathological diagnosis is performed at the tissue collecting institution following the World Health Organization (WHO) standards(6 (link)). The initial diagnosis is reviewed by in-house neuropathologists to assure a measure of consistency across samples. To date, 874 complete frozen sample sets have been accrued, of those 389 are Glioblastoma Multiforme, 122 are Astrocytomas, 113 are Oligodendrogliomas, 33 are Mixed with the reminder still unclassified.
Clinical data on the patients is collected prospectively until the patient’s death through the NABTC Operations Office at M.D. Anderson Cancer Center, Houston, Texas and the NABTT Operations office at the Johns Hopkins University, Baltimore, MD. The clinical data collected is updated into the Rembrandt database on a quarterly basis.
In order to assure consistency in the collection, shipment, processing, assaying, storage, data retrieval and dissemination, we have put together a series of standard operating procedures (SOPs) that have resulted in a streamlined, high-throughput operation capable of handling large numbers of samples in a consistent, operator-independent fashion. Consistency of data over time is continuously monitored by looking for any signs of batch effect in the analyses.
Madhavan S., Zenklusen J.C., Kotliarov Y., Sahni H., Fine H.A, & Buetow K. (2009). Rembrandt: Helping Personalized Medicine Become a Reality Through Integrative Translational Research. Molecular cancer research : MCR, 7(2), 157-167.
Publication 2009
Adult Astrocytoma BLOOD Brain Neoplasms Diagnosis Freezing Frozen Sections Glioblastoma Multiforme Glioma Malignant Neoplasms Neoplasms Neuropathologist Oligodendroglioma pathogenesis Patients Plasma Surgery, Office Therapeutics Tissues
5
Integrated Multi-Omics Analysis of Primary and Recurrent Glioblastoma

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Astrocytoma Europeans Freezing Gene Expression Genome Glioblastoma Glioma Homo sapiens Mutation Neoplasms Patients Pharmacotherapy Radiotherapy RNA-Seq Tissues

Most recents protocols related to «Astrocytoma»

1
Cell culture of glioma and microglia
The normal microglia HMC3 (cat. no. CRL-3304), glioblastoma A172 (cat. no. CRL-1620) and LN-18 (cat. no. CRL-2610) and astrocytoma SW1783 (cat. no. HTB-13) cell lines were acquired from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Inc.) supplemented with 10% foetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C with 5% CO2.
Yang J., Zhang Q., Yang Z., Shu J., Zhang L., Yao Y., Wang X, & Liu X. (2023). KIF18A interacts with PPP1CA to promote the malignant development of glioblastoma. Experimental and Therapeutic Medicine, 25(4), 154.
Publication 2023
Astrocytoma Cell Lines Culture Media Glioblastoma Microglia Penicillins Streptomycin
2
Immunohistofluorescence of Kir4.1 in U-251 Astrocytoma
The human U-251 astrocytoma cell line (U-251MG, RRID:CVCL 0021) was cultured in DMEM high glucose medium with 10% heat-inactivated foetal bovine serum (FBS) and penicillin–streptomycin. Cells seeded on Nunc Lab-TekII Chamber Slide™ were treated overnight with 1 µg/ml tunicamycin (Sigma) or vehicle before being fixed 10 min with 2% paraformaldehyde in PBS and further processed for immunohistofluorescence with rabbit anti-Cter Kir4.1356-375 and mouse or human HR anti-e1 serum followed by the donkey AF488-coupled F(ab’)2 anti-rabbit IgG and AF594-coupled F(ab’)2 anti-mouse or anti-human IgGs. For competition experiments (with e1-preadsorbed sera), mouse (1:100) or HR (1:50) anti-e1 sera were incubated 36 h at 4°C with e1 peptide at 20 µg/ml in PBS supplemented with 2% BSA, centrifuged (14 000 g) for 30 min to remove antibody complexes before being applied to tissue sections at desired concentration. Slides were coverslipped with Prolong Gold DAPI mounting medium before taking pictures at ×40 objective under the fluorescent microscope at fixed exposure time.
Nicot A.B., Harb J., Garcia A., Guillot F., Mai H.L., Mathé C.V., Morille J., Vallino A., Dugast E., Shah S.P., Lefrère F., Moyon M., Wiertlewski S., Le Berre L., Renaudin K., Soulillou J.P., van Pesch V., Brouard S., Berthelot L, & Laplaud D.A. (2023). Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation. Brain Communications, 5(2), fcad044.
Full text: Click here
Publication 2023
anti-IgG Astrocytoma Cell Lines Cells DAPI Equus asinus Fetal Bovine Serum Glucose Gold Homo sapiens Immunoglobulins Microscopy Mus paraform Penicillins Peptides Rabbits Serum Streptomycin Tissues Tunicamycin
3
Awake Surgery for Dominant and Non-Dominant Glioma
As an observational retrospective study, we reviewed a cohort of 80 patients who underwent awake surgery with intraoperative direct electrical mapping for dominant and nondominant hemispheres. All patients were treated at Department of Neurosurgery, Tangdu Hospital, Airforce Medical University, from January 2013 to December 2021. The inclusion criteria were (1) age ≥ 18 years, (2) newly diagnosed glioma, including astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, anaplastic astrocytoma, anaplastic oligoastrocytoma, and glioblastoma, based on the WHO 2007 classification. The WHO 2016 classification was applied in 2017-2019 (31 cases), and the WHO 2021 classification of glioma was applied in 2021 (18 cases). The exclusion criteria included biopsy and incomplete MRI data calculating the tumor volume.
Demographic, clinical, and histological data were collected and analyzed from patients and neurocognitive and functional outcomes. The Institutional Review Board at Tangdu Hospital approved the study (TDLL-202210-18).
Wang Y., Guo S., Wang N., Liu J., Chen F., Zhai Y., Wang Y., Jiao Y., Zhao W., Fan C., Xue Y., Gao G., Ji P, & Wang L. (2023). The clinical and neurocognitive functional changes with awake brain mapping for gliomas invading eloquent areas: Institutional experience and the utility of The Montreal Cognitive Assessment. Frontiers in Oncology, 13, 1086118.
Full text: Click here
Publication 2023
Anaplasia Anaplastic Oligodendroglioma Astrocytoma Astrocytoma, Anaplastic Biopsy Electricity Ethics Committees, Research Glioblastoma Multiforme Glioma Mixed Oligodendroglioma-Astrocytoma Neurosurgical Procedures Oligodendroglioma Operative Surgical Procedures Patients
4
Profiling Pediatric CNS Tumors
This study of pediatric central nervous system tumors was approved by the Institutional Review Board Study #00030211. Tumor and non-tumor tissues were collected from patients treated at Dartmouth Hitchcock Medical Center from 1993 to 2017. Patients consented to use of tissues for research purposes. Histopathologic tumor type and grade for each sample were re-reviewed according to the 2021 WHO classification of CNS tumors and categorized into the major tumor types5 (link). Tumor types included in this study are astrocytoma, embryonal tumors, ependymoma, glioneuronal/neuronal tumors, glioblastoma, and Schwannoma. The average age at diagnosis of subjects from whom the tumor tissues were derived from in this study was 9.3 (range: 0.75 – 18). Male subjects accounted for 62.9% of the tumor samples and female subjects accounted for 37.1% of the tumor samples. Non-tumor brain tissues were obtained from pediatric patients with epilepsy who underwent surgical resection. The average age at diagnosis of subjects from whom the non-tumor samples were derived from was 6.2 (0.58 – 11). Male subjects accounted for 33.3% of the non-tumor samples and female subjects accounted for 66.7% of the non-tumor samples. Specific demographic characteristics of patients for the study are provided in Table 1 and sample information for each subject are provided in Supplementary Table 1.
Lee M.K., Azizgolshani N., Shapiro J.A., Nguyen L.N., Kolling F.W., Zanazzi G.J., Frost H.R, & Christensen B.C. (2023). Tumor type and cell type-specific gene expression alterations in diverse pediatric central nervous system tumors identified using single nuclei RNA-seq. Research Square.
Full text: Click here
Publication Preprint 2023
Astrocytoma Brain Central Nervous System Neoplasms Diagnosis Embryonal Neoplasm Ependymoma Epilepsy Ethics Committees, Research Glioblastoma Multiforme Males Neoplasms Neurilemmoma Neurons Operative Surgical Procedures Patients Tissues Woman
5
Pathological Diagnosis of CNS Tumors
Pathological diagnosis of tumors within this study was based on the 2021 WHO classification of CNS tumors to the extent possible; however, many cases had insufficient information for precise classification using this system and some broader categories were also used29 (link). Available information on tumor pathologies were reviewed and samples were grouped into seven general pathological categories for further analysis by a neuropathologist (CGE). These categories included glioblastoma, IDH-wildtype (GBM, IDH-WT); astrocytoma, IDH-mutant (Astro, IDH-mt, Grade 2–4); oligodendroglioma (Oligo, IDH-mt, Grade 2–3); pleomorphic xanthoastrocytoma (PXA, Grade 2–3); and pilocytic astrocytoma (PA). A subset of tumors did not fall into one of those diagnostic categories and were grouped based on their grade: other high-grade glioma (HGG; Grade 3–4) and other low-grade glioma (LGG; Grade 1–2). Overall survival (OS) was obtained from public databases or calculated from electronic medical records as time from radiographic diagnosis to date of death. Records from 13 adult patients treated with BRAF-targeted therapy were further reviewed to determine treatment type(s), duration, response, and time to progression(s).
We ran an optimal cut-point analysis using maximally selected rank statistics to identify any age inflection points that significantly corresponded with survival in our overall cohort and found inflection points at 34 and 51 years (Supplementary Fig. 3). Consequently, for the purposes of this study, we defined age interval groups as <18, 18–34, 35–50, and >50 years of age.
Schreck K.C., Langat P., Bhave V.M., Li T., Woodward E., Pratilas C.A., Eberhart C.G, & Bi W.L. (2023). Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. NPJ Precision Oncology, 7, 23.
Full text: Click here
Publication 2023
Adult Age Groups Astrocytoma BRAF protein, human Central Nervous System Neoplasms Diagnosis Disease Progression Glioblastoma Glioma Grade II Astrocytomas Malignant Glioma Neoplasms Neuropathologist Oligodendroglioma Oligonucleotides Pilocytic Astrocytoma X-Rays, Diagnostic

Top products related to «Astrocytoma»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
3
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
4
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
5
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
6
Dmem f12 by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia
DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.
7
U87mg by American Type Culture Collection
Sourced in United States, China, Italy, Germany, Japan, United Kingdom
U87MG is a human glioblastoma cell line derived from a malignant brain tumor. It is a well-established model system used in cancer research and drug discovery studies.
8
Fetal calf serum (fcs) by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, France, China, Switzerland, Australia, Austria, Italy, Japan, Canada, Belgium, Brazil, Spain, New Zealand, Netherlands, Denmark, Israel, Sweden, Ireland, Poland, Holy See (Vatican City State), Bulgaria, Argentina, Hungary, Macao
Fetal calf serum is a nutrient-rich cell culture supplement derived from the blood of bovine fetuses. It provides a complex mixture of proteins, growth factors, and other components that support the growth and proliferation of cells in in vitro cell culture systems.
9
Lipofectamine 2000 by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
10
Glutamax by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, France, Switzerland, Canada, Japan, Australia, China, Belgium, Italy, Denmark, Spain, Austria, Netherlands, Sweden, Ireland, New Zealand, Israel, Gabon, India, Poland, Argentina, Macao, Finland, Hungary, Brazil, Slovenia, Sao Tome and Principe, Singapore, Holy See (Vatican City State)
GlutaMAX is a chemically defined, L-glutamine substitute for cell culture media. It is a stable source of L-glutamine that does not degrade over time like L-glutamine. GlutaMAX helps maintain consistent cell growth and performance in cell culture applications.

More about "Astrocytoma"

Astrocytomas are a type of glial tumor that develop from astrocytes, the star-shaped glial cells found in the brain and spinal cord.
These tumors can occur in both children and adults, with varying degrees of aggressiveness.
Astrocytomas range from low-grade, slow-growing tumors to high-grade, rapidly proliferating glioblastomas.
Symptoms may include headaches, seizures, vision problems, and neurological deficits, depending on the tumor's location and infiltration.
Accurate diagnosis and optimal treatment planning are crucial for managing astrocytomas and improving patient outcomes.
Researchers studying astrocytomas can leverage AI-driven comparisons with tools like PubCompare.ai to streamline their work and uncover insights more efficiently.
PubCompare.ai helps researchers locate relevant protocols from literature, pre-prints, and patents, then identify the best protocols and products for reproducible, accurate findings.
This can be particularly useful when working with cell culture models, such as the U87MG astrocytoma cell line, which is commonly used in astrocytoma research.
Effective cell culture techniques, including the use of media like DMEM, DMEM/F12, and Fetal Calf Serum, as well as supplements like Penicillin, Streptomycin, and GlutaMAX, can be crucial for maintaining and studying astrocytoma cell lines.
Transfection reagents like Lipofectamine 2000 may also be employed to introduce genetic modifications or reporter constructs into astrocytoma cells, enabling more detailed investigations.
By leveraging AI-powered tools and optimizing their research workflows, scientists can deepen their understanding of astrocytomas, leading to more effective diagnostic and therapeutic approaches for patients afflicted with these complex brain tumors.